Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253008 | 0.93 | HTR1D (0.62) | HTR1DKDRFLT1FLT4HTR1B | |
| SCHEMBL7253556 | 0.88 | HTR1D (0.46) | HTR1DKDRHTR7BACE1KMO | |
| SCHEMBL7256527 | 0.85 | HTR1D (0.43) | HTR1DHTR7BACE1KMOKCNH2 | |
| SCHEMBL7253398 | 0.83 | HTR1D (0.48) | HTR1DKDRHTR7BACE1KMO | |
| SCHEMBL7256491 | 0.82 | HTR1D (0.47) | HTR1DKDRHTR7BACE1KMO | |
| SCHEMBL7256498 | 0.81 | EEF2K (0.46) | HTR1DHTR7BACE1CHEK1KMO | |
| SCHEMBL7253520 | 0.81 | HTR1D (0.44) | HTR1DHTR7BACE1CHEK1KMO | |
| SCHEMBL7686744 | 0.80 | HTR1D (0.40) | HTR1DHTR7BACE1KMOMAP4K4 | |
| SCHEMBL7253012 | 0.78 | HTR1D (0.42) | HTR1DHTR7BACE1FYNKMO | |
| SCHEMBL7253584 | 0.78 | HTR1D (0.42) | HTR1DHTR7BACE1KMOMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | claimed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | claimed |
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | disclosed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-6380242-B1 | FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS | NPS ALLELIX CORP. (CA) | 2002-04-30 | — | — | US | disclosed |
| EP-1140074-A1 | INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038677-A1 | INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | CNR1, CNR2, KCNH1 | HTR1D 128/4885KDR 2144/4885FLT1 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.